Nitric oxide control of MYCN expression and multi drug resistance genes in tumours of neural origin

Current Pharmaceutical Design

Volumn 16, Issue 4, 2010, Pages 431-439

  Porro, Antonio ^a,b   Chrochemore, Christophe ^a,c   Cambuli, Francesco ^a   Iraci, Nunzio ^a   Contestabile, Antonio ^a   Perini, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b EPFL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ABC transporter genes; MYCN; Neuroblastoma; Neuronal tumours; Nitric oxide

Indexed keywords

1 [2 (2 AMINOETHYL) N (2 AMMONIOETHYL)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; ABC TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RETINOIC ACID; UNCLASSIFIED DRUG; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

CELL PROLIFERATION; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; TUMOR GROWTH; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY;

ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; NITRIC OXIDE; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EID: 77949433737     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790232112     Document Type: Review

References (91)

1. Ramsay G, Stanton L, Schwab M, Bishop JM. Human protooncogene N-myc encodes nuclear proteins that bind DNA. Mol Cell Biol 1986; 6: 4450-7.
2. Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, et al. Identification and characterization of the protein encoded by the human N-myc oncogene. Science 1986; 232: 768-72.
3. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-8.
4. Schwab M, Varmus HE, Bishop JM, Grzeschik KH, Naylor SL, Sakaguchi AY, et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984; 308: 288-91.
5. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 1989; 41: 153-74.
6. Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci USA 1994; 91: 5523-7.
7. Schneider SS, Hiemstra JL, Zehnbauer BA, Taillon-Miller P, Le Paslier DL, Vogelstein B, et al. Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. Mol Cell Biol 1992; 12: 5563-70.
8. Reiter JL, Brodeur GM. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics 1996; 32: 97-103.
9. Brodeur GM, Seeger RC. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications.
10. Cancer Genet Cytogenet 1986; 19: 101-11.
11. Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987; 47: 4248-53.
12. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6.
13. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
14. Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 1995; 55: 721-6.
15. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000; 18: 18-26.
16. Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a pediatric oncology group study. J Clin Oncol 1998; 16: 2007-17.
17. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
18. Lutz W, Schwab M. In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells. Oncogene 1997; 15: 303-15.
19. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004; 204: 179-87.
20. Hogarty MD, Brodeur GM. Wild-type sequence of MYCN in neuroblastoma cell lines. Int J Cancer 1999; 80: 630-1.
21. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211-7.
22. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 1991; 251: 186-9.
23. Perini G, Diolaiti D, Porro A, Della Valle G. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci USA 2005; 102: 12117-22.
24. McArthur GA, Laherty CD, Queva C, Hurlin PJ, Loo L, James L, et al. The Mad protein family links transcriptional repression to cell differentiation. Cold Spring Harb Symp Quant Biol 1998; 63: 423-33.
25. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 2000; 20: 556-62.
26. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008; 9: R150.
27. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008; 3: 611-24.
28. Dildrop R, Zimmerman K, DePinho RA, Yancopoulos GD, Tesfaye A, Alt FW. Differential expression of myc-family genes during development: normal and deregulated N-myc expression in transgenic mice. Curr Top Microbiol Immunol 1988; 141: 100-9.
29. Rosenbaum H, Webb E, Adams JM, Cory S, Harris AW. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. EMBO J 1989; 8: 749-55.
30. Breit S, Schwab M. Suppression of MYC by high expression of NMYC in human neuroblastoma cells. J Neurosci Res 1989; 24: 21-8.
31. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992; 359: 423-6.
32. Kretzner L, Blackwood EM, Eisenman RN. Transcriptional activities of the Myc and Max proteins in mammalian cells. Curr Top Microbiol Immunol 1992; 182: 435-43.
33. Benvenisty N, Leder A, Kuo A, Leder P. An embryonically expressed gene is a target for c-Myc regulation via the c-Mycbinding sequence. Genes Dev 1992; 6: 2513-23.
34. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-8.
35. Gaubatz S, Meichle A, Eilers M. An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by cmyc. Mol Cell Biol 1994; 14: 3853-62.
36. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6: 635-45.
37. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998; 94: 363-74.
38. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 2003; 4: 484-90.
39. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol 2007; 8: 284-95.
40. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128: 707-19.
41. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
42. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, et al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 2008; 68: 9654-62.
43. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. Myc influences global chromatin structure. EMBO J 2006; 25: 2723-34.
44. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V, et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006; 8: 764-70.
45. Cleveland JL, Huleihel M, Bressler P, Siebenlist U, Akiyama L, Eisenman RN, et al. Negative regulation of c-myc transcription involves myc family proteins. Oncogene Res 1988; 3: 357-75.
46. Penn LJ, Brooks MW, Laufer EM, Land H. Negative autoregulation of c-myc transcription. EMBO J 1990; 9: 1113-21.
47. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, et al. Activation of tissue translutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci USA 2007; 104: 18682-7.
48. Grady EF, Schwab M, Rosenau W. Expression of N-myc and c-src during the development of fetal human brain. Cancer Res 1987; 47: 2931-6.
49. Jakobovits A, Schwab M, Bishop JM, Martin GR. Expression of Nmyc in teratocarcinoma stem cells and mouse embryos. Nature 1985; 318: 188-91.
50. Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, et al. Differential expression of myc family genes during murine development. Nature 1986; 319: 780-3.
51. Downs KM, Martin GR, Bishop JM. Contrasting patterns of myc and N-myc expression during gastrulation of the mouse embryo. Genes Dev 1989; 3: 860-9.
52. Hirning U, Schmid P, Schulz WA, Rettenberger G, Hameister H. A comparative analysis of N-myc and c-myc expression and cellular proliferation in mouse organogenesis. Mech Dev 1991; 33: 119-25.
53. Strieder V, Lutz W. Regulation of N-myc expression in development and disease. Cancer Lett 2002; 180: 107-19.
54. Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alboran IM, Olson JM, et al. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 2006; 66: 8655-61.
55. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, et al. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008; 27: 1478-88.
56. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003; 130: 15-28.
57. Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984; 226: 1335-7.
58. Nau MM, Brooks BJ, Jr., Carney DN, Gazdar AF, Battey JF, Sausville EA, et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci USA 1986; 83: 1092-6.
59. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-95.
60. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995; 31A: 505-10.
61. Ciani E, Severi S, Contestabile A, Bartesaghi R. Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. J Cell Sci 2004; 117: 4727-37.
62. Ciani E, Calvanese V, Crochemore C, Bartesaghi R, Contestabile A. Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. J Cell Sci 2006; 119: 3161-70.
63. Williams EL, Djamgoz MB. Nitric oxide and metastatic cell behaviour. Bioessays 2005; 27: 1228-38.
64. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-34.
65. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
66. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
67. Moncada S, Palmer RM, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 1709-15.
68. Murad F. The nitric oxide-cyclic GMP signal transduction system for intracellular and intercellular communication. Recent Prog Horm Res 1994; 49: 239-48.
69. Kerwin JF, Jr., Lancaster JR, Jr., Feldman PL. Nitric oxide: a new paradigm for second messengers. J Med Chem 1995; 38: 4343-62.
70. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
71. Punjabi CJ, Laskin DL, Heck DE, Laskin JD. Production of nitric oxide by murine bone marrow cells. Inverse correlation with cellular proliferation. J Immunol 1992; 149: 2179-84.
72. Yang W, Ando J, Korenaga R, Toyo-oka T, Kamiya A. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun 1994; 203: 1160-7.
73. Peunova N, Enikolopov G. Nitric oxide triggers a switch to growth arrest during differentiation of neuronal cells. Nature 1995; 375: 68-73.
74. Murillo-Carretero M, Ruano MJ, Matarredona ER, Villalobo A, Estrada C. Antiproliferative effect of nitric oxide on epidermal growth factor-responsive human neuroblastoma cells. J Neurochem 2002; 83: 119-31.
75. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001; 93: 1879-85.
76. Liu J, Li C, Qu W, Leslie E, Bonifant CL, Buzard GS, et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther 2004; 3: 709-14.
77. Bonavida B, Khineche S, Huerta-Yepez S, Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 2006; 9: 157-73.
78. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 2005; 65: 516-25.
79. Hirst D, Robson T. Targeting nitric oxide for cancer therapy. J Pharm Pharmacol 2007; 59: 3-13.
80. Contestabile A, Monti B, Ciani E. Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. Curr Med Chem 2003; 10: 2147-74.
81. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005; 76: 126-52.
82. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
83. Hemish J, Nakaya N, Mittal V, Enikolopov G. Nitric oxide activates diverse signaling pathways to regulate gene expression. J Biol Chem 2003; 278: 42321-9.
84. Kroncke KD. Nitrosative stress and transcription. Biol Chem 2003; 384 :1365-77.
85. Pilz RB, Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 2003; 93: 1034-46.
86. Contestabile A. Regulation of transcription factors by nitric oxide in neurons and in neural-derived tumor cells. Prog Neurobiol 2008; 84: 317-28.
87. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001; 33: 475-9.
88. Ciani E, Guidi S, Della Valle G, Perini G, Bartesaghi R, Contestabile A. Nitric oxide protects neuroblastoma cells from apoptosis induced by serum deprivation through cAMP-response element-binding protein (CREB) activation. J Biol Chem 2002; 277: 49896-902.
89. Coco S, Tonini GP, Stigliani S, Scaruffi P. Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies. Curr Pharm Des 2009; 15(4): 448-55.
90. Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009; 15(4): 456-62.
91. Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I. Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009; 15(4): 436-47.